NCT06731478 2026-03-16
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3 Recruiting
Clinical Trials
29 trialsNCT05152147 2026-02-27
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT06532006 2026-02-27
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Phase 3 Recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT04661150 2026-01-30
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT05980481 2025-09-29
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
RemeGen Co., Ltd.
Phase 2/3 Active not recruiting
NCT05002127 2025-08-07
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
ALX Oncology Inc.
Phase 2/3 Active not recruiting
NCT04082364 2025-06-08
MAHOGANY
MacroGenics
Phase 2/3 Completed
NCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT05207722 2024-12-12
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Celularity Incorporated
Phase 1/2 Terminated
NCT04281576 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
NovoCure Ltd.
Phase NA Completed
NCT04908813 2024-04-15
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
Shanghai Henlius Biotech
Phase 2 Active not recruiting
NCT06098898 2023-10-25
Safety and Efficacy of NK510 to Treat Gastric Cancer
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05765357 2023-03-13
Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT05091528 2022-08-18
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Silverback Therapeutics
Phase 1/2 Terminated
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT01602406 2020-12-19
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
Novartis
Phase 1 Completed
NCT01402401 2020-12-10
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
Novartis
Phase 2 Terminated
NCT03680560 2020-03-31
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Cogent Biosciences, Inc.
Phase 1 Terminated
NCT01748773 2019-10-09
TOXAG
Hoffmann-La Roche
Phase 2 Completed
NCT01461057 2018-08-09
JOSHUA
Hoffmann-La Roche
Phase 2 Completed
NCT01839500 2018-03-29
EVIDENCE
Hoffmann-La Roche
Completed
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT01260194 2016-11-02
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
Hoffmann-La Roche
Phase 4 Terminated
NCT01384253 2016-09-30
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Orano Med LLC
Phase 1 Completed
NCT01130337 2015-10-01
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT02005484 2014-08-11
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
Hoffmann-La Roche
Phase 2 Terminated